Ulcerative colitis is an inflammatory bowel disease that affects the gastrointestinal tract characterized by abdominal pain, bloody diarrhea, malnutrition, malabsorption, and weight loss. It involves only the colon, and the commonest sides are the rectum and sigmoid colon. Immune thrombocytopenic purpura (ITP) is an autoimmune disorder characterized by autoantibodies directed against the platelet antigen leading to thrombocytopenia. However, the commonest extraintestinal manifestations of ulcerative colitis are arthritis, mouth ulcer, uveitis, and pyoderma gangrenosum. There are a few cases reported that showed there is an association between ulcerative colitis and ITP. Eltrombopag (thrombopoietin receptor agonist) use in the management of chronic ITP, its role in activation hematopoietic bone marrow receptors of the platelets. Management of ulcerative colitis is immunosuppressive medication; however, here we report a 22 year old who has ulcerative colitis and ITP received Eltrombopag and discovered that his endoscopy finding showed remission of ulcerative colitis.

Ulcerative colitis (UC) is an autoimmune inflammatory disorder characterized by an ulcer of the colon and rectum. The primary etiology is unknown; however, there are multiple factors that play a role in the pathogenesis of UC, such as genetic factors (HLA system), alteration of normal bowel flora, immune dysfunction, and environmental factors. Eltrombopag can be used safely as upfront medication in the management of ulcerative colitis as well as ITP, and it showed a beneficial effect in both disorders.

**KEYWORDS**
eltrombopag, IBD, inflammatory bowel diseases, ITP, ulcerative colitis
manifest as skin bleeding or manifested as systemic in severe cases bleeding like intracranial hemorrhage (ICH). ITP can be acquired or inherited disorders.4

Eltrombopag (EPAG) is a thrombopoietin agonist that can be used orally to enhance platelet production from the bone marrow. It is used for the treatment of chronic ITP, especially for those who are resistant to steroids.5

Standard treatment for ulcerative colitis depends on the extent of involvement and disease severity. UC can be treated with several medications, including 5-ASA drugs such as sulfasalazine and mesalazine and corticosteroids such as prednisone6.

However, here we present the responsiveness of UC to EPAG that is used for the treatment of UC associated ITP.

2 | CASE PRESENTATION

A 21-year-old gentleman with no chronic medical conditions has been suffering from diarrhea for the last 4-6 months. He has 10-12 bowel motions on average per day. The volume and consistency differ each time, but mostly it is watery (mucous) and moderate amount.

He also has on and off blood coming with stool, mild to moderate in amount. Sometimes, he also has abdominal cramps, which improve with the bowel motion. He denied nausea/vomiting. He also denied any fever, weight loss, loss of appetite. There is no joint pain and vision problems. He had 2-3 Visits to ED and PHCC, and he was managed symptomatically with IBS and hemorrhoids.

He underwent sigmoidoscopy and showed ulceration in the rectum and sigmoid colon, and features consistent with ulcerative colitis. (see Figures 1 and 2). A biopsy sent, and the result showed:

- Left colon, biopsy showed: Intramucosal lymphoid aggregates.
- Rectum and sigmoid biopsies showed Chronic active colitis, moderate. Negative for granuloma, dysplasia, or carcinoma.

Full colon colonoscopy was done and showed proctosigmoiditis, mayo grade 2-3, same findings of sigmoidoscopy.

His initial complete blood count showed thrombocytopenia and high calprotectin (see Table 1), which was labeled as ITP after being excluding the other causes of thrombocytopenia. He started on mesalamine topical and oral (Mesalazine tabs 400 mg BID for two months) and Eltrombopag (Dosage of Eltrombopag was 50 mg orally 4 times /day for 4 months) for ITP after he refused steroids, and he has been followed in the clinic for the response to the management. Repeated colonoscopy after eight weeks showed a significant decrease in sigmoidoprotitis (see Figures 3 and 4) and the improvement of his platelets (see Table 2).

3 | DISCUSSION

Inflammatory bowel disease (ulcerative colitis and Crohn disease) both can be presented with intestinal manifestations such as bloody diarrhea, tenesmus, abdominal pain, malabsorption, and weight loss.7 However, inflammatory bowel diseases can be present with extraintestinal manifestation such as musculoskeletal (arthritis), mouth (aphthous

| TABLE 1 | Low platelet and high Calprotectin |
|----------|-----------------------------------|
| Detail   | Value w/Units | Flags | Normal Range |
| Hemoglobin | 13.7 gm/dL | normal | 13.0-17.0 |
| Platelet  | 35 × 10^3/μL | low | 150-400 |
| Calprotectin | 1,108 mg/Kg | High | 5-50 |
ulcer), ocular (uveitis), and hepatobiliary (primary biliary cirrhosis and primary sclerosing cholangitis). ITP is one of the rare extraintestinal manifestations of IBD.8

ITP is characterized by systemic hemorrhagic diathesis due to excessive thrombocyte destruction. ITP can be classified into acute (newly diagnosed) and chronic types according to clinical course. In general, acute ITP is more common in infants than adults and often recovers spontaneously, whereas chronic ITP is typically recurrent and occasionally refractory to therapy.9 ITP is a disease of exclusion, and it is diagnosed by low platelet enlargement of megakaryocytes in the bone marrow.10

Upon the literature review, there are a few cases that reported the association between IBD and ITP. However, there are no clear data support that ITP is common among Crohn's disease and ulcerative colitis.

There is no clear data provided to know the underlying pathogenesis of ITP related to IBD. However, some theories showed there is antigen similarity between platelet surface antigen and gut lumen, particularly bacterial surface antigen, in addition to the increasing level of TH1 and CD4 in both ITP and IBD.11

Standard management of UC is mesalamine, steroids, and immunosuppressive medications. However, when was started Eltrombopag for ITP, the sour patient showed marked improvement in both platelets and regression of UC.

Eltrombopag is a small-molecule nonpeptide TPO-R agonist administered orally. It can effectively increase platelet counts and reduce bleeding events in patients with chronic ITP, with an overall response rate of 60% to 80%. Eltrombopag is well tolerated and has a good safety profile in adults.12

Upon literature review, there are no studies or case reports that document the association between Eltrombopag and regression of IBD. Despite there is no clear pathogenesis, but the immunomodulatory effect of Eltrombopag could decrease the inflammatory response of IBD.

4 | CONCLUSION

Eltrombopag can be used safely as upfront medication in the management of ulcerative colitis and ITP, and it showed a beneficial effect in both disorders.

ACKNOWLEDGMENTS

The authors would like to acknowledge the internal medicine residency program for scientific support. Published with written consent of the patient.

CONFLICT OF INTEREST

None declared.

AUTHOR CONTRIBUTIONS

Elabbass Abdulmahmuod: writing editing, final approval. Elrazi Ali: writing editing, final approval. Mohamed Yassin: writing editing, final approval. Mohanad Ahmed: writing editing, final approval.

STATEMENT OF ETHICS

This case was approved by the Hamad Medical Corporation's Medical Research Center. And the patient consented to the publication of his case.
DATA AVAILABILITY STATEMENT
Data available on request.

ORCID
Elabbass A. Abdelmahmuod https://orcid.org/0000-0001-9330-5740
Elrazi Ali https://orcid.org/0000-0002-8967-433X
Mohanad A. Ahmed https://orcid.org/0000-0002-1144-8076
Mohamed A. Yassin https://orcid.org/0000-0002-1760-2935

REFERENCES
1. Ulcerative Colitis; NIDDK [Internet]. [cited 2020 Sep 8]. Available from: https://www.niddk.nih.gov/health-information/digestive-diseases/ulcerative-colitis
2. Ford AC, Moayyedi P, Hanauer SB, Kirsner JB. Ulcerative colitis [Internet]. Vol. 346, BMJ (Online). British Medical Journal Publishing Group; 2013 [cited 2020 Sep 8]. Available from: https://www.bmj.com/content/346/bmj.f432
3. Danese S, Fiocchi C. Ulcerative colitis. Vol. 365, New England Journal of Medicine. Massachusetts Medical Society; 2011. p. 1713–25. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMra1102942
4. Ahmed MA, Yassin MA. Low-dose eltrombopag in a patient with chronic idiopathic thrombocytopenic purpura post sleeve gastrectomy. Case Rep Oncol. 2020;655-658.
5. Chouhan JD, Herrington JD. Treatment options for chronic refractory idiopathic thrombocytopenic purpura in adults: Focus on romiplostim and eltrombopag. Pharmacotherapy. 2010;30:666-683.
6. Zlatanic J, Korelitz BI, Wisch N, et al. Inflammatory bowel disease and immune thrombocytopenic purpura: Is there a correlation? Am J Gastroenterol. 1997;92(12 suppl):2285-2288.
7. Manzano ML, Yela C, Castellano G, Rodriguez S, Solis JA. Idiopathic thrombocytopenic purpura and pancytopenia in a patient with Crohn’s disease: A new association [16]. Am J Gastroenterol. 1996;91:1678-1679.
8. Motamed F, Zandieh F, Sedighi M. Crohn’s disease and idiopathic thrombocytopenic purpura in a patient with ectodermal dysplasia and immunodeficiency. Iran J Allergy Asthma Immunol. 2006;5(3):143-145.
9. Baudard M, Molina T, Benfiguig K, Bethoux JP, Zittoun R. Idiopathic thrombocytopenic purpura associated with Crohn’s disease. Haematologica. 1998;83(1):92-93.
10. Rasheed MA, Alsaud AE, Razzaq S, Fadul A, Yassin MA. Cerebral venous thrombosis in a patient with immune thrombocytopenia, an apparent paradox. Case Rep Oncol. 2020;588-594.
11. Manceñido Marcos N, Erdozain Sosa JC, Pajares Villarroya R, et al. Púrpura trombocitopénica idiopática como manifestación extraintestinal de la enfermedad de Crohn. Gastroenterol Hepatol. 2004;27(6):368-371.
12. Bidika E, Fayyaz H, Salib M, et al. Romiplostim and eltrombopag in immune thrombocytopenia as a second-line treatment. Cureus. 2020;12(8).

How to cite this article: Abdelmahmuod EA, Ali E, Ahmed MA, Yassin MA. Eltrombopag and its beneficial role in management of ulcerative Colitis associated with ITP as an upfront therapy case report. Clin Case Rep. 2021;9:1416–1419. https://doi.org/10.1002/ccr3.3783